Navega Therapeutics
Biotechnology, High BLF Dr, San Diego, , 92130, California, 12625, United States, 1-10 Employees
Phone Number: 85********
Who is NAVEGA THERAPEUTICS
Around 1.5 billion people around the world suffer from chronic pain, with more than 100 million in the US alone. Conventional treatment for chronic pain consists mostly of opioid narcotic...
Read More
- Headquarters: 12625 High BLF Dr, San Diego, California, 92130, United States
- Date Founded: 2018
- Employees: 1-10
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
- CEO: Ana Moreno
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from NAVEGA THERAPEUTICS
Navega Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Navega Therapeutics
Answer: Navega Therapeutics's headquarters are located at High BLF Dr, San Diego, , 92130, California, 12625, United States
Answer: Navega Therapeutics's phone number is 85********
Answer: Navega Therapeutics's official website is https://navegatx.com
Answer: Navega Therapeutics's revenue is $1 Million to $5 Million
Answer: Navega Therapeutics's SIC: 8731
Answer: Navega Therapeutics has 1-10 employees
Answer: Navega Therapeutics is in Biotechnology
Answer: Navega Therapeutics contact info: Phone number: 85******** Website: https://navegatx.com
Answer: Around 1.5 billion people around the world suffer from chronic pain, with more than 100 million in the US alone. Conventional treatment for chronic pain consists mostly of opioid narcotics. However, opioids have failed us as the United States is currently undergoing an opioid epidemic. Sadly, over 120 Americans die each day of an opioid overdose. We have developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific and long-lasting. So how does this work? We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way. In our proof of concept, we have demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels. Importantly, mice are not numb and can continue feeling mechanical stimulation, such as touch. We believe that patients should not have to decide whether they live a life with pain, or one with the risk of addiction.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month